Weil GJ, et al. - Through large community studies performed in five countries between October 2016 and November 2017, researchers assessed the safety of ivermectin with diethylcarbamazine and albendazole in combination (IDA) and diethylcarbamazine plus albendazole in combination (DA) in various endemic settings for lymphatic filariasis (LF) elimination. Over 26,000 people were examined for LF infection, treated, and evaluated for adverse events (AEs) post-treatment. Twelve percent of individuals had AEs; this rate was similar following treatment with either IDA or DA. Those who had filarial worms in their blood prior to treatment had AEs more often; in this subgroup, AEs were more often seen after IDA vs DA, but no excess of severe or serious AEs post-IDA was recorded. In various LF-endemic populations, IDA was well tolerated, and the safety of IDA was comparable to the safety of DA for use as a mass drug administration regimen for LF eradication in regions that currently receiving DA. After IDA or DA treatment, there was no significant difference in posttreatment AE rates and severity.